COX2/PTGS2 Cancer Research Results

COX2/PTGS2, cycloocygenase-2 (Cox-2) mRNA and Cox-2 protein: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Cyclooxygenase-2 (COX-2) is an enzyme that plays a critical role in the conversion of arachidonic acid to prostaglandins, which are lipid compounds involved in various physiological processes, including inflammation, pain, and fever. COX-2 is an inducible enzyme, meaning its expression is typically low in normal tissues but can be upregulated in response to inflammatory stimuli, growth factors, and certain oncogenic signals.
-Cyclooxygenase-2 (COX-2), the rate-limiting enzyme in prostaglandin biosynthesis, plays a key role in inflammation and circulatory homeostasis.
-COX-2 is an inducible enzyme that is upregulated in response to pro-inflammatory signals, including cytokines (e.g., IL-1β, TNF-α) and growth factors.

COX-2 is often overexpressed in various tumors, including colorectal, breast, lung, and prostate cancers.
The prostaglandins produced by COX-2, particularly prostaglandin E2 (PGE2), have several effects that can facilitate cancer progression:
Cell Proliferation: PGE2 can promote the proliferation of cancer cells by activating signaling pathways such as the PI3K/Akt and MAPK pathways.
Nonselective NSAIDs, such as aspirin and ibuprofen, inhibit both COX-1 and COX-2. Epidemiological studies have suggested that regular use of NSAIDs may reduce the risk of certain cancers, particularly colorectal cancer.
Drugs specifically targeting COX-2, such as celecoxib, have been developed.

COX-2 and xanthine oxidase are ROS-producing pro-oxidant enzymes that contribute to inflammation. Elevated COX‑2 levels, often found in inflammatory conditions or certain types of cancers, can contribute to increased production of ROS.


Scientific Papers found: Click to Expand⟱
2819- CUR,  Chemo,    Curcumin as a hepatoprotective agent against chemotherapy-induced liver injury
- Review, Var, NA
*hepatoP↑, *Inflam↓, *antiOx↑, *lipid-P↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, *GSTs↑, *ROS↓, *ALAT↓, *AST↓, *MDA↓, *NRF2↑, *COX2/PTGS2↑, *NF-kB↓, *ICAM-1↓, *MCP1/CCL2↓, *HO-1↑, CXCc↓,
6981- Form,    Formononetin: a review of its source, pharmacology, drug combination, toxicity, derivatives, and drug delivery systems
- Review, Var, NA - Review, AD, NA - Review, PSA, NA
BioAv↝, *memory↑, *ROS↓, *AChE↓, *NF-kB↓, *Keap1↝, *NRF2↑, *Inflam↓, *PGC-1α↝, *HO-1↓, *p‑tau↓, *cognitive↑, *BDNF↑, *5HT↑, *Stroke↓, *PARP1↓, *AIF↓, *Casp3↓, NP/CIPN↓, *neuroP↑, *NGF↑, *TNF-α↓, *IL1β↓, *IL18↓, *IL6↓, *VCAM-1↓, *pol-M2 MC↑, *hepatoP↑, *AST↓, *ALAT↓, *LC3II↑, *Beclin-1/ATG6↑, *p62↑, *COX2/PTGS2↑, *MMP↑, *ATP↑, *GSH↑, *Catalase↑, *GPx↑, *MDA↓, *antiPs↑, *AntiDiabetic↑, *glucose↓, *Insulin↑, *GutMicro↑, *Obesity↓, COX2/PTGS2↓, cycD1/CCND1↓, TumCCA↑, EGFR↓, GSK‐3β↑, Mcl-1↓, *toxicity↓, TumCP↓, Hif1a↓, VEGF↓, ERK↓, LAMs↓, Cyt‑c↑, Casp9↑, Casp3↑, PARP↑, TumCD↑, mitA↑, BACH1↓, P53↓, ROS↑, PD-1↓, NF-kB↓, *Bacteria↓, *AntiViral↑, *mt-ROS?, *PI3K↓, *chemoP↑, ChemoSen↑, Synergy↑, *toxicity↓, *BioAv↑, *BioAv↑, *Synergy↑, *antiAll↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

GSK‐3β↑, 1,  

Cell Death(tgid=5) ⓘ

Casp3↑, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   Mcl-1↓, 1,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

EGFR↓, 1,   ERK↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↓, 1,   PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   mitA↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCP↓, 1,  

Migration(tgid=13) ⓘ

BACH1↓, 1,   LAMs↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   CXCc↓, 1,   NF-kB↓, 1,   PD-1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   ChemoSen↑, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,  

Functional Outcomes(tgid=23) ⓘ

NP/CIPN↓, 1,  
Total Targets: 28

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 2,   GPx↑, 2,   GSH↑, 2,   GSTs↑, 1,   HO-1↓, 1,   HO-1↑, 1,   Keap1↝, 1,   lipid-P↓, 1,   MDA↓, 2,   NRF2↑, 2,   ROS↓, 2,   mt-ROS?, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

Insulin↑, 1,   PGC-1α↝, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 2,   ATP↑, 1,   glucose↓, 1,  

Cell Death(tgid=5) ⓘ

AIF↓, 1,   Casp3↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

PI3K↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   LC3II↑, 1,   p62↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

PARP1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

VCAM-1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↑, 2,   ICAM-1↓, 1,   IL18↓, 1,   IL1β↓, 1,   IL6↓, 1,   Inflam↓, 2,   pol-M2 MC↑, 1,   MCP1/CCL2↓, 1,   NF-kB↓, 2,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 1,   AChE↓, 1,   BDNF↑, 1,   NGF↑, 1,  

Protein Aggregation(tgid=19) ⓘ

p‑tau↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 2,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   AST↓, 2,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

antiAll↑, 1,   AntiDiabetic↑, 1,   antiPs↑, 1,   chemoP↑, 1,   cognitive↑, 1,   hepatoP↑, 2,   memory↑, 1,   neuroP↑, 1,   Obesity↓, 1,   Stroke↓, 1,   toxicity↓, 2,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 1,   Bacteria↓, 1,   GutMicro↑, 1,  
Total Targets: 62

Scientific Paper Hit Count for: COX2/PTGS2, cycloocygenase-2 (Cox-2) mRNA and Cox-2 protein
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:1  prod#:%  Target#:66  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page